123 related articles for article (PubMed ID: 10951339)
1. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma.
King TC; Akerley W; Fan AC; Moore T; Mangray S; Hsiu Chen M; Safran H
Cancer; 2000 Aug; 89(4):769-73. PubMed ID: 10951339
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma.
Safran H; King T; Choy H; Gollerkeri A; Kwakwa H; Lopez F; Cole B; Myers J; Tarpey J; Rosmarin A
Cancer; 1996 Sep; 78(6):1203-10. PubMed ID: 8826941
[TBL] [Abstract][Full Text] [Related]
3. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
[TBL] [Abstract][Full Text] [Related]
4. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
King TC; Estalilla OC; Safran H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):4-11. PubMed ID: 10210535
[TBL] [Abstract][Full Text] [Related]
5. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
6. Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.
Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
Cancer Biother Radiopharm; 2012 May; 27(4):227-33. PubMed ID: 22489661
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
8. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
Monzó M; Rosell R; Sánchez JJ; Lee JS; O'Brate A; González-Larriba JL; Alberola V; Lorenzo JC; Núñez L; Ro JY; Martín C
J Clin Oncol; 1999 Jun; 17(6):1786-93. PubMed ID: 10561216
[TBL] [Abstract][Full Text] [Related]
10. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
[TBL] [Abstract][Full Text] [Related]
11. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
[TBL] [Abstract][Full Text] [Related]
12. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.
Socinski MA
Oncologist; 1999; 4(5):408-16. PubMed ID: 10551557
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies.
Huncharek M; Kupelnick B; Geschwind JF; Caubet JF
Cancer Lett; 2000 May; 153(1-2):219-26. PubMed ID: 10779652
[TBL] [Abstract][Full Text] [Related]
14. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
15. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
[TBL] [Abstract][Full Text] [Related]
16. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
17. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.
Perez-Soler R; Kemp B; Wu QP; Mao L; Gomez J; Zeleniuch-Jacquotte A; Yee H; Lee JS; Jagirdar J; Ling YH
Clin Cancer Res; 2000 Dec; 6(12):4932-8. PubMed ID: 11156254
[TBL] [Abstract][Full Text] [Related]
18. p53 mutations predict non-small cell lung carcinoma response to radiotherapy.
Matsuzoe D; Hideshima T; Kimura A; Inada K; Watanabe K; Akita Y; Kawahara K; Shirakusa T
Cancer Lett; 1999 Jan; 135(2):189-94. PubMed ID: 10096428
[TBL] [Abstract][Full Text] [Related]
19. Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma.
Natsume T; Kobayashi M; Fujimoto S
Cancer; 2001 Jul; 92(2):386-94. PubMed ID: 11466694
[TBL] [Abstract][Full Text] [Related]
20. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
